Related Experiment Video
Updated: Aug 1, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
Simvastatin Reduces Doxorubicin-Induced Cardiotoxicity: Effects beyond Its Antioxidant Activity
Michela Pecoraro1, Stefania Marzocco1, Raffaella Belvedere1
1Department of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy.
Abstract:
This study aimed to evaluate if Simvastatin can reduce, and/or prevent, Doxorubicin (Doxo)-induced cardiotoxicity. H9c2 cells were treated with Simvastatin (10 µM) for 4 h and then Doxo (1 µM) was added, and the effects on oxidative stress, calcium homeostasis, and apoptosis were evaluated after 20 h. Furthermore, we evaluated the effects of Simvastatin and Doxo co-treatment on Connexin 43 (Cx43) expression and localization, since this transmembrane protein forming gap junctions is widely involved in cardioprotection. Cytofluorimetric analysis showed that Simvastatin co-treatment significantly reduced Doxo-induced cytosolic and mitochondrial ROS overproduction, apoptosis, and cytochrome c release. Spectrofluorimetric analysis performed by means of Fura2 showed that Simvastatin co-treatment reduced calcium levels stored in mitochondria and restored cytosolic calcium storage. Western blot, immunofluorescence, and cytofluorimetric analyses showed that Simvastatin co-treatment significantly reduced Doxo-induced mitochondrial Cx43 over-expression and significantly increased the membrane levels of Cx43 phosphorylated on Ser368. We hypothesized that the reduced expression of mitochondrial Cx43 could justify the reduced levels of calcium stored in mitochondria and the consequent induction of apoptosis observed in Simvastatin co-treated cells. Moreover, the increased membrane levels of Cx43 phosphorylated on Ser368, which is responsible for the closed conformational state of the gap junction, let us to hypothesize that Simvastatin leads to cell-to-cell communication interruption to block the propagation of Doxo-induced harmful stimuli. Based on these results, we can conclude that Simvastatin could be a good adjuvant in Doxo anticancer therapy. Indeed, we confirmed its antioxidant and antiapoptotic activity, and, above all, we highlighted that Simvastatin interferes with expression and cellular localization of Cx43 that is widely involved in cardioprotection.
Insights
Simvastatin protects against Doxorubicin-induced cardiotoxicity by reducing oxidative stress and apoptosis. It also modulates Connexin 43 (Cx43) expression, potentially blocking harmful signals during chemotherapy.
Area of Science:
- Cardiology
- Pharmacology
- Cell Biology
Background:
- Doxorubicin (Doxo) is a potent chemotherapy agent with significant cardiotoxicity.
- Oxidative stress, calcium dysregulation, and apoptosis are key mechanisms in Doxo-induced heart damage.
- Connexin 43 (Cx43) plays a crucial role in cardioprotection and cell-to-cell communication.
Purpose of the Study:
- To investigate Simvastatin's potential to prevent or reduce Doxorubicin-induced cardiotoxicity.
- To evaluate Simvastatin's effects on oxidative stress, calcium homeostasis, and apoptosis in H9c2 cells treated with Doxo.
- To examine the impact of Simvastatin and Doxo co-treatment on Cx43 expression and localization.
Main Methods:
- H9c2 cells were treated with Simvastatin and Doxorubicin.
- Evaluated oxidative stress (ROS), calcium levels (Fura2), and apoptosis.
- Analyzed Connexin 43 (Cx43) expression and localization using Western blot, immunofluorescence, and cytofluorimetry.
Main Results:
- Simvastatin significantly reduced Doxo-induced reactive oxygen species (ROS) production, apoptosis, and cytochrome c release.
- Simvastatin normalized cytosolic calcium levels and reduced mitochondrial calcium storage.
- Simvastatin decreased mitochondrial Cx43 and increased membrane-bound phosphorylated Cx43 (Ser368), suggesting altered gap junction function.
Conclusions:
- Simvastatin exhibits antioxidant and antiapoptotic properties, mitigating Doxo-induced cardiotoxicity.
- Simvastatin influences Cx43 expression and localization, potentially by reducing mitochondrial Cx43 and increasing membrane Cx43 phosphorylation.
- These findings suggest Simvastatin could be a valuable adjuvant in Doxorubicin chemotherapy to protect the heart.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

